Paradigm Biopharmaceuticals Limited (ASX:PAR)
Australia · Delayed Price · Currency is AUD 0.2800
+0.0150 (5.66%)
Sep 5, 2025, 4:10 PM AEST
ASX:PAR Revenue
Paradigm Biopharmaceuticals had revenue of 16.70K AUD in the half year ending December 31, 2024, with 254.56% growth. This brings the company's revenue in the last twelve months to 16.70K, down -454.56% year-over-year.
Revenue (ttm)
16.70K
Revenue Growth
-454.56%
P/S Ratio
6,663.51
Revenue / Employee
n/a
Employees
n/a
Market Cap
111.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 79.22K | 58.67K | 285.52% |
| Jun 30, 2021 | 20.55K | - | - |
| Jun 30, 2020 | - | - | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.79B |
| Ansell | 3.06B |
| Telix Pharmaceuticals | 1.01B |
| Mesoblast | 26.23M |